The Canadian apheresis registry

Area of Science:

• Medical Science
• Hematology
• Neurology

Background:

• Apheresis selectively removes blood components using machines.
• Therapeutic apheresis (TA) treats over 30 diseases in Canada.
• The Canadian Apheresis Group (CAG) was established in 1980 to evaluate TA applications.

Purpose of the Study:

• To provide a forum for information exchange among Canadian apheresis practitioners.
• To develop clinical trials evaluating the efficacy of plasma exchange.
• To ensure appropriate and cost-effective application of therapeutic apheresis.

Main Methods:

• The CAG organized a national database, collecting data from 42 apheresis units.
• Data from over 140,000 plasma exchange procedures were analyzed.
• National practice guidelines were developed and studies were directed.

Main Results:

• Plasma exchange procedures remained stable at approximately 8500 annually between 2002-2006.
• In 2002, hematological disorders accounted for 55% of procedures, and neurological disorders for 40%.
• CAG activities have led to controlled, appropriate shifts in TA application, favoring hematological over neurological treatments.

Conclusions:

• The CAG has fostered rational, cost-effective use of TA in Canada over 22 years.
• CAG activities have promoted knowledge dissemination among apheresis practitioners.
• The CAG's efforts have led to optimal patient care through refined practices and monitored replacement fluids.